KYMR
Income statement / Annual
Last year (2025), Kymera Therapeutics Inc's total revenue was $39.20 M,
a decrease of 16.72% from the previous year.
In 2025, Kymera Therapeutics Inc's net income was -$311.40 M.
See Kymera Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$39.20 M |
$47.07 M |
$78.59 M |
$46.83 M |
$72.83 M |
$34.03 M |
$2.93 M |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$825.00 K
|
$205.00 K
|
| Gross Profit |
$39.20 M
|
$47.07 M
|
$78.59 M
|
$46.83 M
|
$72.83 M
|
$34.03 M
|
$2.11 M
|
-$205.00 K
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
0.72
|
0
|
| Research and Development Expenses |
$316.60 M
|
$240.25 M
|
$189.08 M
|
$164.25 M
|
$137.02 M
|
$62.11 M
|
$37.16 M
|
$17.68 M
|
| General & Administrative Expenses |
$68.20 M
|
$63.53 M
|
$55.04 M
|
$43.83 M
|
$36.35 M
|
$18.23 M
|
$7.98 M
|
$3.77 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$68.20 M
|
$63.53 M
|
$55.04 M
|
$43.83 M
|
$36.35 M
|
$18.23 M
|
$7.98 M
|
$3.77 M
|
| Other Expenses |
$3.80 M
|
$4.93 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$388.60 M
|
$308.71 M
|
$244.12 M
|
$208.08 M
|
$173.36 M
|
$80.34 M
|
$45.14 M
|
$21.45 M
|
| Cost And Expenses |
$388.60 M
|
$308.71 M
|
$244.12 M
|
$208.08 M
|
$173.36 M
|
$80.34 M
|
$45.14 M
|
$21.45 M
|
| Interest Income |
$38.03 M
|
$38.03 M
|
$18.76 M
|
$6.62 M
|
$488.00 K
|
$826.00 K
|
$1.01 M
|
$0.00
|
| Interest Expense |
$249.00 K
|
$249.00 K
|
$196.00 K
|
$176.00 K
|
$175.00 K
|
$115.00 K
|
$46.00 K
|
$16.00 K
|
| Depreciation & Amortization |
$8.31 M
|
$7.37 M
|
$3.57 M
|
$2.98 M
|
$2.40 M
|
$1.76 M
|
$825.00 K
|
$205.00 K
|
| EBITDA |
-$303.06 M |
-$216.24 M |
-$143.20 M |
-$151.66 M |
-$97.65 M |
-$43.72 M |
-$40.38 M |
-$21.25 M |
| EBITDA Ratio |
-7.73
|
-4.59
|
-1.82
|
-3.24
|
-1.34
|
-1.28
|
-13.76
|
0
|
| Operating Income Ratio |
-8.91
|
-5.56
|
-2.11
|
-3.44
|
-1.38
|
-1.36
|
-14.38
|
0
|
| Total Other Income/Expenses Net |
$37.78 M
|
$37.78 M
|
$18.57 M
|
$6.45 M
|
$313.00 K
|
$711.00 K
|
$959.00 K
|
-$16.00 K
|
| Income Before Tax |
-$311.62 M
|
-$223.86 M
|
-$146.96 M
|
-$154.81 M
|
-$100.22 M
|
-$45.59 M
|
-$41.25 M
|
-$21.47 M
|
| Income Before Tax Ratio |
-7.95
|
-4.76
|
-1.87
|
-3.31
|
-1.38
|
-1.34
|
-14.06
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$43.86 K
|
| Net Income |
-$311.40 M
|
-$223.86 M
|
-$146.96 M
|
-$154.81 M
|
-$100.22 M
|
-$45.59 M
|
-$41.29 M
|
-$21.47 M
|
| Net Income Ratio |
-7.94
|
-4.76
|
-1.87
|
-3.31
|
-1.38
|
-1.34
|
-14.07
|
0
|
| EPS |
-3.69 |
-2.98 |
-2.52 |
-2.87 |
-2.09 |
-0.99 |
-0.93 |
-0.48 |
| EPS Diluted |
-3.69 |
-2.98 |
-2.52 |
-2.87 |
-2.09 |
-0.99 |
-0.93 |
-0.48 |
| Weighted Average Shares Out |
$84.39 M
|
$75.04 M
|
$58.37 M
|
$53.93 M
|
$47.99 M
|
$44.56 M
|
$44.53 M
|
$44.53 M
|
| Weighted Average Shares Out Diluted |
$84.39 M
|
$75.04 M
|
$58.37 M
|
$53.93 M
|
$47.99 M
|
$44.56 M
|
$44.53 M
|
$44.53 M
|
| Link |
|
|
|
|
|
|
|
|
